Why the study?
Do metabolic modulators improve symptoms without hemodynamic side effects in patients with ischemic heart disease experiencing angina despite standard therapy?
Do metabolic modulators improve symptoms without hemodynamic side effects in patients with ischemic heart disease experiencing angina despite standard therapy?
Metabolic modulators represent a novel therapeutic paradigm for chronic cardiac ischemia that may avoid the hemodynamic side effects limiting current antianginal medications.
No takes yet. Share an insight, caveat, or question.
May offer hemodynamic-neutral add-on therapy for refractory angina; leaves open need for randomized outcome trials.
Parang et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: